Mixed bag for PPPs

While large pharmaceutical companies have been using public-private partnerships (PPPs) to tap into innovative academic science for years, an analysis by BioCentury Innovations revealed big biotechs are increasingly joining the party, and that, perhaps unexpectedly, one-off deals by small companies comprise the largest proportion.

The data suggest that partnering with academic organizations is not only the province of large pharmas looking to externalize innovation and bolster their pipelines, nor is that their only goal. Instead, big pharmas are turning to PPPs and consortia as vehicles for solving industry-wide problems, and a means to test the waters of precompetitive collaboration...